Table 2

Completed clinical trials with γ-secretase inhibitors in pediatric/young adult oncologic patients (clinicaltrials.gov).

Compound

ClinicalTrials Gov Identifier

Clinical studies

Cancer type

Patients'age


MK0752

NCT00106145

Phase I study

Breast and advanced solid tumors

18 Years and older

MK0752

NCT00100152

Phase I study

T-ALL

12 Months and oldera

RO4929097

NCT01192763

Phase I study

Pancreatic cancer

18 Years and older

RO4929097

NCT01208441

Phase I study

Breast cancer

18 Years and older

RO4929097

NCT01269411

Phase I study

Brain and Central Nervous System Tumors

18 Years and older

RO4929097

NCT01216787

Phase II study

Melanoma (Skin)

18 Years and older

RO4929097

NCT01217411

Phase I study

Breast Cancer

18 Years and older

RO4929097

NCT01151449

Phase II study

Breast Cancer

18 Years and older

RO4929097 with or without Bevacizumab

NCT01270438

Phase II study

Metastatic Colorectal Cancer

18 Years and older

RO4929097

NCT01236586

Phase I/II study

Brain and Central Nervous System Tumors, T-ALL

1 Year to 21 Yearsa

RO4929097

NCT01088763

Phase I/II study

Leukemia

1 Year to 21 Yearsa


aEnrollment of children. T-ALL, T-cell acute lymphoblastic leukemia/lymphoma.

Rota et al. BMC Medicine 2012 10:141   doi:10.1186/1741-7015-10-141

Open Data